Dassault Systèmes, the French 3D experience company, has recently announced that the first heart model from its "Living Heart Project" is now commercially available since May 29, 2015.
Powered by Dassault Systèmes' simulation applications, the 3D simulator of a four-chamber human heart is the first product of its kind. The "Living Heart" model represents a baseline healthy heart, which can be used to study congenital defects or heart disease by modifying the shape and tissue properties in an easy-to-use software editor.
With this model, device manufacturers, researchers, and medical professionals will be able to perform virtual tests and visualise the heart's response in ways that are not possible with traditional physical testing.
Medical devices can also be inserted into the simulator to study their influence on cardiac function, validate their efficacy, and predict reliability under a range of operating conditions. For example, coronary stents can be evaluated for optimal type, size, and placement location to achieve the best performance.
Announced in 2014, the "Living Heart Project" leverages crowdsourcing of its 45 current members to build its models while protecting the intellectual property of each member. Members include regulatory science focused organizations such as the Food and Drug Administration (FDA) and the Medical Device Innovation Consortium (MDIC), as well as technology providers, cardiologists, medical device manufacturers and hospitals such as St. Jude Medical and Mayo Clinic.
This unique crowdsourcing approach has enabled the heart model to be independently tested and included in peer-reviewed scientific journals by project members, and helped Dassault Systèmes deliver the first iteration of the project's commercial product on an accelerated schedule. This achievement demonstrates the effectiveness of the project's approach and reaffirms the opportunity for simulation to address meaningful challenges in cardiovascular disease.
"The availability of the first commercial, physics-based simulated heart marks a significant milestone for digital medical tools that will advance cardiovascular science and directly impact the quality of life of patients," said Scott Berkey, CEO, SIMULIA, Dassault Systèmes. "The 'Living Heart Project' is proof that our technology can potentially change the course of therapies through simulation of the human body. We will continue to collaborate with the biomedical community and our partners to provide technology and applications that will enhance the experience for heart patients everywhere."
In addition to the general availability of the heart simulator, the members of the "Living Heart Project" have collectively identified the highest priority cardiovascular applications for it and associated technological advancements which will help shape the functionality of future versions of the simulator.
Sign up for Computerworld eNewsletters.